Anavex announces ANAVEX 2-73 data
Anavex Life Sciences announced a positive 41-week update from its Phase 2a study in mild-to-moderate Alzheimer's disease patients for ANAVEX 2-73, which targets cellular homeostasis. At 41 weeks, Alzheimer's patients taking a daily oral dose of ANAVEX 2-73 in the exploratory, not yet dose optimized Phase 2a clinical trial, showed a stabilization of cognitive and functional measures. This data of stabilization is promising since Alzheimer's disease is a progressive disease where current therapeutics are only able to temporarily slow the worsening of dementia symptoms and not stop the disease from progressing. At 41 weeks, oral daily dosing between 10mg and 50mg, ANAVEX 2-73 was well tolerated, and no patients discontinued treatment due to adverse events. There were no clinically significant treatment-related adverse events, and no serious adverse events. Pre-specified exploratory analyses included the cognitive and the functional changes from baseline. A continued stabilization of both cognitive and functional measures in patients treated with ANAVEX 2-73 was observed. This correlation was positive with all measured scores.